Astrazeneca Plc ADR (AZN)

$96.34 +1.83 (1.94%)
Market Cap 293.12B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.49
Forward PE 18.16
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 7,709,300
Avg Vol 5,388,800
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 98%
Beta 0.34
Analysts Strong Sell
Price Target $98.44

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
prismmarketview
prismmarketview Jan. 15 at 12:13 AM
AstraZeneca (NASDAQ: $AZN) reiterated its goal of hitting $80 billion in annual revenue by 2030 at JPM, leaning on multiple near‑term FDA launch candidates, a broad antibody‑drug conjugate oncology pipeline, and advancing cell therapy programs with several assets targeting multi‑billion‑dollar peak sales. #AstraZeneca https://prismmarketview.com/jpm26-astrazenecas-path-to-80b-by-2030-paved-with-adcs-cell-therapies-near-term-launches/
0 · Reply
maikl_211
maikl_211 Jan. 14 at 11:18 AM
$CAT $WFC $AZN $MS $GS
0 · Reply
Chipwars
Chipwars Jan. 13 at 11:07 PM
$AZN Why Astrazeneca is leaving the Nasdaq. It's a good thing for the stock. They will be trading in London as before, the NYSE and the Swedish Nasdaq...a lot of room for growth. Read this : https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html
0 · Reply
Chipwars
Chipwars Jan. 13 at 10:48 PM
Finally...someone else gets this. And anyway, Nasdaq or not, $AZN is a strong stock, good diversity away from the Mag 7... and with a dividend
0 · Reply
Steeletwits
Steeletwits Jan. 13 at 9:39 PM
$AZN $GLD $SLV $SPY $WMT
0 · Reply
Kaysaaa81
Kaysaaa81 Jan. 13 at 8:31 PM
$SGMO $AZN On their JPM presentation, they’re building platforms, not just one-off assets. Fabry alone is interesting, but when combined with SGMO’s gene-regulation platform and capsid technology, it aligns with AZN’s “Beyond 2030” focus on gene therapy, cell therapy, and T-cell engagers. Fabry alone draws moderate interest, but as part of a broader platform transaction, the level of interest increases.
1 · Reply
notreload_ai
notreload_ai Jan. 13 at 5:52 PM
$AZN is buying AI startup Modella to speed up cancer drug research. Modella’s AI will help analyze patient data, discover biomarkers, and improve clinical trials. This is AstraZeneca’s first AI acquisition, aiming to make drug development faster and more precise.
0 · Reply
howardlindzon
howardlindzon Jan. 13 at 5:19 PM
$AZN still won’t get them back in Nasdaq 100 over $WMT
2 · Reply
StocktwitsNews
StocktwitsNews Jan. 13 at 5:18 PM
AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline $AZN https://stocktwits.com/news/equity/markets/astrazeneca-buys-boston-based-startup-in-fresh-ai-push-for-cancer-pipeline/cmUXXgSR4I9
0 · Reply
BruniCharting
BruniCharting Jan. 13 at 4:09 PM
$SPY $SLV $GLD $WMT $AZN
0 · Reply
Latest News on AZN
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:15 PM EST - 1 day ago

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 1 day ago

AstraZeneca to acquire Modella AI to speed oncology drug research

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

Jan 13, 2026, 12:02 PM EST - 1 day ago

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Jan 10, 2026, 10:00 AM EST - 4 days ago

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 5 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN BMY LLY MRK NVO PFE

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Jan 8, 2026, 7:12 AM EST - 6 days ago

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Jan 8, 2026, 7:00 AM EST - 6 days ago

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

Jan 6, 2026, 7:44 AM EST - 8 days ago

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

Jan 2, 2026, 1:55 PM EST - 12 days ago

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

BK C CAH CVS

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

Dec 22, 2025, 2:39 AM EST - 23 days ago

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

Dec 22, 2025, 2:22 AM EST - 23 days ago

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 26 days ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX IBB

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 26 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN BMY GILD LLY MRK NVO

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

Dec 19, 2025, 2:30 AM EST - 26 days ago

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 4 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN BMY LLY NVS PFE

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Dec 15, 2025, 4:29 PM EST - 4 weeks ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

Dec 10, 2025, 10:26 AM EST - 5 weeks ago

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Dec 8, 2025, 8:10 AM EST - 5 weeks ago

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Dec 4, 2025, 4:00 PM EST - 5 weeks ago

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

CRM

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Dec 4, 2025, 7:00 AM EST - 5 weeks ago

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Dec 2, 2025, 9:18 AM EST - 6 weeks ago

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

BREAKING: Trump strikes major deal with UK on drug pricing

Dec 1, 2025, 10:15 AM EST - 6 weeks ago

BREAKING: Trump strikes major deal with UK on drug pricing

EWU EWUS FKU FLGB FXB GSK

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

Nov 26, 2025, 12:18 PM EST - 7 weeks ago

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

NVO

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Nov 24, 2025, 12:58 PM EST - 7 weeks ago

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Nov 23, 2025, 7:01 PM EST - 7 weeks ago

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

Nov 21, 2025, 8:22 PM EST - 7 weeks ago

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

AstraZeneca to invest $2 billion as part of US manufacturing push

Nov 21, 2025, 2:05 PM EST - 7 weeks ago

AstraZeneca to invest $2 billion as part of US manufacturing push

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Nov 21, 2025, 2:05 PM EST - 7 weeks ago

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 2 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

JNJ LLY MDT MRK NVO OLMA PFE

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN BIIB GILD GSK JNJ LLY

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 2 months ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV JNJ LLY MRK NVO PFE XLV

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

Nov 14, 2025, 7:06 AM EST - 2 months ago

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

LLY

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

Nov 11, 2025, 7:45 AM EST - 2 months ago

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

AstraZeneca hits record high, cements lead as UK's biggest stock

Nov 11, 2025, 3:42 AM EST - 2 months ago

AstraZeneca hits record high, cements lead as UK's biggest stock

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Nov 10, 2025, 1:39 PM EST - 2 months ago

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Nov 9, 2025, 4:33 PM EST - 2 months ago

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Nov 7, 2025, 9:00 AM EST - 2 months ago

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:26 PM EST - 2 months ago

AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

Nov 6, 2025, 3:28 PM EST - 2 months ago

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

AstraZeneca's 9M and Q3 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 2 months ago

AstraZeneca's 9M and Q3 2025 Financial Results

AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO

Nov 6, 2025, 4:12 AM EST - 2 months ago

AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

Nov 6, 2025, 2:39 AM EST - 2 months ago

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

AstraZeneca beats third-quarter revenue and profit expectations

Nov 6, 2025, 2:04 AM EST - 2 months ago

AstraZeneca beats third-quarter revenue and profit expectations

AstraZeneca wins shareholder backing for NYSE listing in US pivot

Nov 3, 2025, 11:11 AM EST - 2 months ago

AstraZeneca wins shareholder backing for NYSE listing in US pivot

AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

Nov 3, 2025, 11:06 AM EST - 2 months ago

AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

Nov 3, 2025, 9:17 AM EST - 2 months ago

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer

Oct 31, 2025, 1:19 AM EDT - 2 months ago

FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer

BP

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

Oct 24, 2025, 4:51 AM EDT - 2 months ago

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

AstraZeneca hails major breakthroughs with breast-cancer drugs

Oct 20, 2025, 6:53 AM EDT - 3 months ago

AstraZeneca hails major breakthroughs with breast-cancer drugs

AstraZeneca's Datroway extends survival in aggressive breast cancer

Oct 19, 2025, 2:32 AM EDT - 3 months ago

AstraZeneca's Datroway extends survival in aggressive breast cancer

prismmarketview
prismmarketview Jan. 15 at 12:13 AM
AstraZeneca (NASDAQ: $AZN) reiterated its goal of hitting $80 billion in annual revenue by 2030 at JPM, leaning on multiple near‑term FDA launch candidates, a broad antibody‑drug conjugate oncology pipeline, and advancing cell therapy programs with several assets targeting multi‑billion‑dollar peak sales. #AstraZeneca https://prismmarketview.com/jpm26-astrazenecas-path-to-80b-by-2030-paved-with-adcs-cell-therapies-near-term-launches/
0 · Reply
maikl_211
maikl_211 Jan. 14 at 11:18 AM
$CAT $WFC $AZN $MS $GS
0 · Reply
Chipwars
Chipwars Jan. 13 at 11:07 PM
$AZN Why Astrazeneca is leaving the Nasdaq. It's a good thing for the stock. They will be trading in London as before, the NYSE and the Swedish Nasdaq...a lot of room for growth. Read this : https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html
0 · Reply
Chipwars
Chipwars Jan. 13 at 10:48 PM
Finally...someone else gets this. And anyway, Nasdaq or not, $AZN is a strong stock, good diversity away from the Mag 7... and with a dividend
0 · Reply
Steeletwits
Steeletwits Jan. 13 at 9:39 PM
$AZN $GLD $SLV $SPY $WMT
0 · Reply
Kaysaaa81
Kaysaaa81 Jan. 13 at 8:31 PM
$SGMO $AZN On their JPM presentation, they’re building platforms, not just one-off assets. Fabry alone is interesting, but when combined with SGMO’s gene-regulation platform and capsid technology, it aligns with AZN’s “Beyond 2030” focus on gene therapy, cell therapy, and T-cell engagers. Fabry alone draws moderate interest, but as part of a broader platform transaction, the level of interest increases.
1 · Reply
notreload_ai
notreload_ai Jan. 13 at 5:52 PM
$AZN is buying AI startup Modella to speed up cancer drug research. Modella’s AI will help analyze patient data, discover biomarkers, and improve clinical trials. This is AstraZeneca’s first AI acquisition, aiming to make drug development faster and more precise.
0 · Reply
howardlindzon
howardlindzon Jan. 13 at 5:19 PM
$AZN still won’t get them back in Nasdaq 100 over $WMT
2 · Reply
StocktwitsNews
StocktwitsNews Jan. 13 at 5:18 PM
AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline $AZN https://stocktwits.com/news/equity/markets/astrazeneca-buys-boston-based-startup-in-fresh-ai-push-for-cancer-pipeline/cmUXXgSR4I9
0 · Reply
BruniCharting
BruniCharting Jan. 13 at 4:09 PM
$SPY $SLV $GLD $WMT $AZN
0 · Reply
Chipwars
Chipwars Jan. 13 at 3:59 PM
$AZN nice tiny dip earlier, good for adding into...
0 · Reply
Stocktwits
Stocktwits Jan. 13 at 3:59 PM
A new episode of Retail Edge is out!! $SPY • Powell probe headlines & Fed independence • Gold/silver at new highs $SLV $GLD • Credit card rate cap hits lenders • Meme ideas + China momentum • $WMT replaces $AZN in the Nasdaq 100 Watch as @Steeletwits and @BruniCharting break it all down! 👇 https://www.youtube.com/watch?v=hr0re5Um7XU
3 · Reply
resq1
resq1 Jan. 13 at 3:05 PM
$NVO and $AZN should be at bidding wars right now at this insane valuation for $OMER
0 · Reply
unton
unton Jan. 13 at 1:43 PM
$PFE $MRNA $AZN $JNJ $DCOY one single pill for all types of COVID.”
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 11:11 AM
$WMT is set to join Nasdaq-100 on Jan. 20, 2026 — what does this mean for investors? 🚀 WMT's upcoming Nasdaq inclusion emphasizes its shift to a tech-driven enterprise, with shares already up 4.7% since Jan. 7 in anticipation. Meanwhile, $AZN will exit as part of the index reshuffle. Find out how this change could impact your portfolio 👉 https://www.zacks.com/stock/news/2816202/walmart-stock-gaining-steam-ahead-of-debut-on-nasdaq-100?cid=sm-stocktwits-2-2816202-body-28526&ADID=SYND_STOCKTWITS_TWEET_2_2816202_BODY_28526
0 · Reply
Sarge986
Sarge986 Jan. 12 at 7:56 PM
. New Walmart Price Target After Stock Listing Update $WMT $ICE $GOOGL $AZN #MarketRecon .. https://pro.thestreet.com/trade-ideas/new-walmart-price-target-after-stock-listing-update
0 · Reply
Quantumup
Quantumup Jan. 12 at 7:42 PM
TD Cowen reiterated $BBIO Buy; PT 95 $ALNY $PFE $AZN - $IONS NVO Here's what TD Cowen had to say: Attruby Q4 sales of $146MM beat expectations by 9%, leading to an impressive first full year of sales of $362MM. New patient starts surged with an estimated 25% NBRx share, signaling growing market leadership. The late-stage pipeline anchors the next leg of growth, with Phase III wins for LGMD21 and ADH1, while infi's Q1 data could easily support a best-in-class profile — each with $1B+ potential.
0 · Reply
davoid57
davoid57 Jan. 12 at 4:17 PM
$WMT $AZN $GOOGL @Chipwars that sucks for $AZN
1 · Reply
Stocktwits
Stocktwits Jan. 12 at 3:53 PM
$WMT Walmart keeps stacking catalysts: • New all-time highs • Added to Nasdaq 100 (replacing $AZN) • Partnership with Gemini $GOOGL • Drone delivery expansion via Google’s Wing Retail leadership staying intact.
0 · Reply
theoptionsplug
theoptionsplug Jan. 12 at 12:00 AM
$WMT broke out to the upside, as we expected. Should be able to drift back up to highs at $117.45 this week 📈 On Friday, Nasdaq said that Walmart will replace $AZN Astrazeneca in the Nasdaq-100, effective Jan. 20th 👀
0 · Reply
Stockwise14
Stockwise14 Jan. 11 at 4:39 PM
$AZN $HYFT $NOVO.X $PFE Super bullish, chart is primed, float is pretty much locked up, collab news will def take this into the double digit, add a little FOMO and blue skies!!
0 · Reply
Twills08
Twills08 Jan. 11 at 4:31 PM
$HYFT I certainly don’t use AI to determine my plays, but this is a very good summation of what to expect from tomorrow’s pending PR. This isn’t a “will they?” scenario. The company has repeatedly stated that they have very large collaborators interested/signing on, and they will be announcing prior to open tomorrow. I cannot encourage you enough to get in preH or at the bell. Based upon their fairly incredible influenza announcement on Friday, this will likely be a deal in the billions of dollars. You don’t find a cure for the flu (we are talking universal vaccine here) without having $PFE $NOVO.X or $AZN come knocking. Price target for Monday: $8-10 just off the Influenza announcement from Friday AH. If they announce a $1-2 billion dollar collaboration, all bets are off. Looking at $15-20 per share. I will add the rest of the attachments in the comments below. DD and decide for yourself. NFA as always and GLTY.
3 · Reply